Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.97, while Vertex Pharmaceuticals Incorporated trades at $529.07 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPQ | VRTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $529.65 |
52-Week Low | $53.77 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.01, up 0.55% today, with a bullish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with an options income strategy, generating monthly distributions. Recent news highlights its role in retirement income portfolios but notes tax implications for distributions. Key support sits at $59, with resistance at $60.
The outlook remains positive for income-seeking investors, supported by institutional buying and media coverage. Risks include tax treatment of distributions and market volatility affecting the underlying Nasdaq holdings. Analyst sentiment is mixed due to high RSI levels suggesting potential overbought conditions near-term.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
